RU94034104A - Способ увеличения цитотоксичности химиотерапевтического агента, набор для лечения и средство для производства лекарств - Google Patents
Способ увеличения цитотоксичности химиотерапевтического агента, набор для лечения и средство для производства лекарствInfo
- Publication number
- RU94034104A RU94034104A RU94034104/14A RU94034104A RU94034104A RU 94034104 A RU94034104 A RU 94034104A RU 94034104/14 A RU94034104/14 A RU 94034104/14A RU 94034104 A RU94034104 A RU 94034104A RU 94034104 A RU94034104 A RU 94034104A
- Authority
- RU
- Russia
- Prior art keywords
- chemotherapeutic agent
- treatment
- cytotoxicity
- agent
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Изобретение обеспечивает способы увеличения цитотоксичности химиотерапевтического агента в отношении твердых опухолей, чувствительных к лечению названным химиотерапевтическим агентом, включающие введение млекопитающему с такой опухолью, приблизительно от получаса до двадцати четырех часов до введения химиотерапевтического агента, усиливающего цитотоксичность количества соединения формулы 1. Изобретение обеспечивает также наборы для лечения таких опухолей, которые включают химиотерапевтический агент и усиливающее цитотоксичность количество оксида 1,2,4-бензотриозина, определенного формулой 1. Изобретение обеспечивает применение соединения формулы 1, способного вызывать эффект усиления цитотоксичности в отношении раковой опухоли, для производства лекарственного средства для терапевтического введения млекопитающим с такими опухолями, от приблизительно получаса до двадцати четырех часов до начала лечения названной опухоли химиотерапевтическим агентом
Claims (1)
- Изобретение обеспечивает способы увеличения цитотоксичности химиотерапевтического агента в отношении твердых опухолей, чувствительных к лечению названным химиотерапевтическим агентом, включающие введение млекопитающему с такой опухолью, приблизительно от получаса до двадцати четырех часов до введения химиотерапевтического агента, усиливающего цитотоксичность количества соединения формулы 1. Изобретение обеспечивает также наборы для лечения таких опухолей, которые включают химиотерапевтический агент и усиливающее цитотоксичность количество оксида 1,2,4-бензотриозина, определенного формулой 1. Изобретение обеспечивает применение соединения формулы 1, способного вызывать эффект усиления цитотоксичности в отношении раковой опухоли, для производства лекарственного средства для терапевтического введения млекопитающим с такими опухолями, от приблизительно получаса до двадцати четырех часов до начала лечения названной опухоли химиотерапевтическим агентом.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US125609 | 1993-09-22 | ||
US08/125,609 US5484612A (en) | 1993-09-22 | 1993-09-22 | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
Publications (2)
Publication Number | Publication Date |
---|---|
RU94034104A true RU94034104A (ru) | 1996-11-10 |
RU2148406C1 RU2148406C1 (ru) | 2000-05-10 |
Family
ID=22420569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU94034104A RU2148406C1 (ru) | 1993-09-22 | 1994-09-22 | Способ увеличения цитотоксичности химиотерапевтического агента, набор для лечения |
Country Status (22)
Country | Link |
---|---|
US (4) | US5484612A (ru) |
EP (2) | EP0972517B1 (ru) |
JP (1) | JPH07215882A (ru) |
KR (1) | KR100383402B1 (ru) |
AT (2) | ATE193827T1 (ru) |
AU (1) | AU690132B2 (ru) |
CA (1) | CA2132578C (ru) |
CZ (1) | CZ289742B6 (ru) |
DE (2) | DE69433889T2 (ru) |
DK (2) | DK0649658T3 (ru) |
ES (2) | ES2224517T3 (ru) |
GR (1) | GR3034360T3 (ru) |
HU (1) | HUT71119A (ru) |
IL (1) | IL111025A (ru) |
MY (1) | MY112405A (ru) |
NO (1) | NO943524L (ru) |
NZ (2) | NZ264502A (ru) |
PT (2) | PT649658E (ru) |
RU (1) | RU2148406C1 (ru) |
SG (1) | SG52568A1 (ru) |
SK (1) | SK282178B6 (ru) |
UA (1) | UA49787C2 (ru) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597582A (en) * | 1995-09-12 | 1997-01-28 | Sanofi | Oral gel capsule formulation of 1,2,4-benzotriazine oxides |
US5672702A (en) * | 1995-12-04 | 1997-09-30 | Sanofi | Process for preparing 3 amino 1, 2, 4-benzotriazine dioxide |
EP1014990B1 (en) * | 1997-03-07 | 2006-09-06 | Sanofi-Aventis U.S. LLC | Antitumor combination of 3-amino-1,2,4-benzotriazine 1,4-dioxide/paclitaxel/platinum |
US6103698A (en) | 1997-03-13 | 2000-08-15 | Basf Aktiengesellschaft | Dolastatin-15 derivatives in combination with taxanes |
EP1030675B1 (en) * | 1997-11-14 | 2009-08-12 | The General Hospital Corporation | Treatment of hematologic disorders |
US6074626A (en) * | 1998-03-20 | 2000-06-13 | Molecular Radiation Management, Inc. | Radioactive cisplatin in the treatment of cancer |
US6620382B1 (en) * | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
US6819761B1 (en) * | 1999-09-16 | 2004-11-16 | Silicon Laboratories, Inc. | Programmable constant current “off hook” circuit |
AU775373B2 (en) | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
EP1254122B1 (de) | 1999-12-21 | 2008-09-17 | UFZ-UMWELTFORSCHUNGSZENTRUM Leipzig-Halle GmbH | Neue 3-substituierte 1,2,4-benzotriazine, verfahren zu ihrer herstellung und ihre verwendung zur behandlung und prophylaxe von tumorerkrankungen |
US6989139B2 (en) * | 2000-02-15 | 2006-01-24 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
AUPQ641100A0 (en) * | 2000-03-23 | 2000-04-15 | Australia Nuclear Science & Technology Organisation | Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents |
CA2307278A1 (en) * | 2000-04-28 | 2001-10-28 | University Of British Columbia | Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine |
US6338859B1 (en) * | 2000-06-29 | 2002-01-15 | Labopharm Inc. | Polymeric micelle compositions |
RU2166945C1 (ru) * | 2000-08-08 | 2001-05-20 | Ефимова Лариса Степановна | Радиосенсибилизирующее вещество для лечения онкологических заболеваний |
US6586460B1 (en) | 2001-04-02 | 2003-07-01 | The Board Of Regents For Oklahoma State University | Heteroarotinoids containing urea or thiourea linker |
AT412703B (de) | 2001-12-04 | 2005-06-27 | Vis Vitalis Lizenz & Handels | Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung |
NZ521436A (en) * | 2002-09-17 | 2005-07-29 | Auckland Uniservices Ltd | DNA- targeted benzotriazine 1,4-dioxides and their use in cancer therapy |
US7138520B2 (en) * | 2003-01-13 | 2006-11-21 | Massachusetts Institute Of Technology | Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same |
CA2456569A1 (en) * | 2003-03-14 | 2004-09-14 | Auckland Uniservices Limited | Benzoazine mono-n-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments |
US7816521B2 (en) | 2004-03-01 | 2010-10-19 | Auckland Uniservices Limited | 1,2,4-benzotriazine-1,4-dioxides |
WO2006104406A1 (en) * | 2005-03-31 | 2006-10-05 | Auckland Uniservices Limited | Tricyclic 1,2,4-triazine oxides and compositions therefrom for therapeutic use in cancer treatments |
US20090136521A1 (en) * | 2005-10-03 | 2009-05-28 | Genetix Pharmaceuticals , Inc. | Method for Selectively Depleting Hypoxic Cells |
US20070212360A1 (en) * | 2006-01-17 | 2007-09-13 | Denko Nicholas C | Modulation of mitochondrial oxygen consumption for therapeutic purposes |
US7834178B2 (en) * | 2006-03-01 | 2010-11-16 | Bristol-Myers Squibb Company | Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
WO2007108272A1 (ja) * | 2006-03-23 | 2007-09-27 | Tmrc Co., Ltd. | 癌治療用キットおよび癌治療用医薬組成物 |
AU2009209515A1 (en) * | 2008-01-28 | 2009-08-06 | Milux Holding Sa | Blood clot removal device, system, and method |
WO2009126705A2 (en) | 2008-04-10 | 2009-10-15 | Virginia Commonwealth University | Induction of tumor hypoxia for cancer therapy |
US9316632B2 (en) * | 2009-03-17 | 2016-04-19 | Marshall University Research Corporation | Methods of screening chemotherapeutic agents and treating cancer |
AT511159A1 (de) | 2011-02-16 | 2012-09-15 | Selo Medical Gmbh | Pharmazeutische zusammensetzungen enthaltend selenit- oder selenathältige verbindungen |
CN104105692B (zh) | 2011-12-07 | 2016-06-29 | 思研(Sri)国际顾问与咨询公司 | 作为结核分枝杆菌靶向药物的苯并三嗪氧化物 |
MX367055B (es) | 2012-06-26 | 2019-08-02 | Del Mar Pharmaceuticals | El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa. |
US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
TW202116767A (zh) * | 2019-07-01 | 2021-05-01 | 美商古拉森療法公司 | β腎上腺素激動劑及其使用方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4001410A (en) * | 1972-02-01 | 1977-01-04 | Bayer Aktiengesellschaft | 3-amino-1,2,4-benzotriazine-1,4-di-n-oxide compositions and method of using same |
US5175287A (en) * | 1986-09-25 | 1992-12-29 | S R I International | Process for preparing 1,2,4-benzotriazine oxides |
US5597582A (en) * | 1995-09-12 | 1997-01-28 | Sanofi | Oral gel capsule formulation of 1,2,4-benzotriazine oxides |
-
1993
- 1993-09-22 US US08/125,609 patent/US5484612A/en not_active Expired - Lifetime
-
1994
- 1994-09-16 KR KR1019940023493A patent/KR100383402B1/ko not_active IP Right Cessation
- 1994-09-19 ES ES99118533T patent/ES2224517T3/es not_active Expired - Lifetime
- 1994-09-19 EP EP99118533A patent/EP0972517B1/en not_active Expired - Lifetime
- 1994-09-19 EP EP94202693A patent/EP0649658B1/en not_active Expired - Lifetime
- 1994-09-19 SG SG1996006227A patent/SG52568A1/en unknown
- 1994-09-19 PT PT94202693T patent/PT649658E/pt unknown
- 1994-09-19 DE DE69433889T patent/DE69433889T2/de not_active Expired - Fee Related
- 1994-09-19 DE DE69424915T patent/DE69424915T2/de not_active Expired - Fee Related
- 1994-09-19 DK DK94202693T patent/DK0649658T3/da active
- 1994-09-19 ES ES94202693T patent/ES2147567T3/es not_active Expired - Lifetime
- 1994-09-19 AT AT94202693T patent/ATE193827T1/de not_active IP Right Cessation
- 1994-09-19 AT AT99118533T patent/ATE270553T1/de not_active IP Right Cessation
- 1994-09-19 DK DK99118533T patent/DK0972517T3/da active
- 1994-09-19 PT PT99118533T patent/PT972517E/pt unknown
- 1994-09-21 NZ NZ264502A patent/NZ264502A/en not_active IP Right Cessation
- 1994-09-21 UA UA94095838A patent/UA49787C2/ru unknown
- 1994-09-21 AU AU74117/94A patent/AU690132B2/en not_active Ceased
- 1994-09-21 CA CA002132578A patent/CA2132578C/en not_active Expired - Fee Related
- 1994-09-21 NZ NZ299690A patent/NZ299690A/en not_active IP Right Cessation
- 1994-09-22 IL IL111025A patent/IL111025A/en not_active IP Right Cessation
- 1994-09-22 CZ CZ19942326A patent/CZ289742B6/cs not_active IP Right Cessation
- 1994-09-22 MY MYPI94002526A patent/MY112405A/en unknown
- 1994-09-22 HU HU9402726A patent/HUT71119A/hu unknown
- 1994-09-22 RU RU94034104A patent/RU2148406C1/ru not_active IP Right Cessation
- 1994-09-22 JP JP6227568A patent/JPH07215882A/ja active Pending
- 1994-09-22 SK SK1148-94A patent/SK282178B6/sk unknown
- 1994-09-22 NO NO943524A patent/NO943524L/no unknown
-
1995
- 1995-05-24 US US08/448,705 patent/US5670502A/en not_active Expired - Lifetime
-
1997
- 1997-05-07 US US08/852,616 patent/US6121263A/en not_active Expired - Fee Related
-
2000
- 2000-04-26 US US09/558,786 patent/US6277835B1/en not_active Expired - Fee Related
- 2000-09-06 GR GR20000402048T patent/GR3034360T3/el not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU94034104A (ru) | Способ увеличения цитотоксичности химиотерапевтического агента, набор для лечения и средство для производства лекарств | |
EA200300294A1 (ru) | Способы лечения связанного с bcl-2 нарушения с использованием bcl-2-антисмысловых олигомеров | |
CA2501651A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
CA2464758A1 (en) | Combination therapy comprising zd6474 and a taxane | |
HUP0303976A2 (hu) | Kombinációs terápia anti-EGFR-ellenanyagok és hormonantagonisták együttes alkalmazásával | |
DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
DE60027719D1 (de) | Krebstherapie | |
DE69426334D1 (de) | Parenterales Busulfan zur Behandlung von malignen Krankheiten | |
JPS62240619A (ja) | 制癌剤 | |
IL102460A (en) | Method for enhancing the immunotherapeutic activity of lymphocytes to decrease the tumor burden by stimulation of lymphocytes in vitro in the presence of anti-cd3-antibody and by co-administration of il-2, kits containing such enhanced lymphocytes and their use in preparation of a medicament for cancer therapy | |
ATE74006T1 (de) | Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken. | |
RU95105973A (ru) | Способ снижения тяжести токсоплазмоза, фармацевтическая композиция, применение производных рифамицина для получения лекарственных препаратов для лечения токсоплазмоза | |
RU2217196C2 (ru) | Способ индукции дифференцировки клеток | |
RU94030808A (ru) | Применение фосфокриатина или фосфоенолпировиноградной кислоты для лечения опухолей и фармацевтические препараты, обладающие противоопухолевой активностью | |
JPS61155324A (ja) | 癌治療薬剤 | |
KR960700734A (ko) | 사람 암에 대한 시스플래틴/타목시펜 배합 치료(Combination cisplatin/tamoxifen therapy for human cancers) | |
CA2531620A1 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
KR927002224A (ko) | 항종양효과증강제 및 항종양제 | |
RU2005115102A (ru) | Новые противоопухолевые соединения | |
CN116492323B (zh) | 一种苯乙烯酸类化合物的新用途 | |
RU2089247C1 (ru) | Способ лечения онкологических больных | |
RU2088247C1 (ru) | Способ повышения эффективности лучевой терапии | |
RU2233662C1 (ru) | Способ профилактики местных лучевых реакций | |
AR124521A1 (es) | Tratamiento para tumores sólidos malignos | |
RU2021814C1 (ru) | Способ лечения инфекционных заболеваний кожи |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20080923 |